Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Ester-C (calcium ascorbate) is a buffered, non-acidic form of vitamin C. It has the same safety profile as ascorbic acid. It is well tolerated and causes less GI irritation at high doses than ascorbic acid. Doses above 2000 mg/day may cause osmotic diarrhoea. It may interact with blood-thinning medications and the bioavailability of some drugs.
Biological and Chemical Classification
Information not yet available for this ingredient profile.
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Vitamins
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Ester-C indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 26 მარ 2026, 14:19
Evidence Distribution
-
Observational / other LOW evidence YELLOWBiochemical components of chicken primordial germ cells are modified by cryopreservation: original analysis by Fourier Transform Infrared (FTIR) microspectroscopy. ↗Sornsan S et al.. Biochemical components of chicken primordial germ cells are modified by cryopreservation: original analysis by Fourier Transform Infrared (FTIR) microspectroscopy.. Poult Sci. 2026. PMID:41833113.PMID 41833113 ↗Journal Poult SciYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41833113/
-
Observational / other LOW evidence YELLOWEffect of primary-secondary synergistic system on the aging resistance of Salix psammophila/polylactic acid composites. ↗Hu J et al.. Effect of primary-secondary synergistic system on the aging resistance of Salix psammophila/polylactic acid composites.. RSC Adv. 2026. PMID:41822776.PMID 41822776 ↗Journal RSC AdvYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41822776/
-
Observational / other LOW evidence YELLOWBio-diesel quality characterization towards bio-jet fuel production using infrared spectroscopy and an interpretable machine learning framework. ↗Chen C et al.. Bio-diesel quality characterization towards bio-jet fuel production using infrared spectroscopy and an interpretable machine learning framework.. J Environ Manage. 2026. PMID:41722311.PMID 41722311 ↗Journal J Environ ManageYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41722311/
-
Observational / other LOW evidence YELLOWAgricultural beneficial microbes accelerate soil degradation of poly(butylene adipate-co-terephthalate) (PBAT) films. ↗He Y et al.. Agricultural beneficial microbes accelerate soil degradation of poly(butylene adipate-co-terephthalate) (PBAT) films.. RSC Adv. 2025. PMID:41409719.PMID 41409719 ↗Journal RSC AdvYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41409719/
-
Observational / other LOW evidence YELLOWDBU-catalysed cascade nucleophilic addition/cyclization to access 7-nitro (ester) imidazo[1,2-a] pyridin-8-amines. ↗Nagineni D et al.. DBU-catalysed cascade nucleophilic addition/cyclization to access 7-nitro (ester) imidazo[1,2-a] pyridin-8-amines.. Org Biomol Chem. 2025. PMID:40951953.PMID 40951953 ↗Journal Org Biomol ChemYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40951953/
-
Observational / other LOW evidence YELLOWPhysicochemical effects of succination in aqueous medium and reactive extrusion on achira (Canna indica L.) starch intended for food industry applications. ↗Aldapa CAG et al.. Physicochemical effects of succination in aqueous medium and reactive extrusion on achira (Canna indica L.) starch intended for food industry applications.. Int J Biol Macromol. 2025. PMID:40774491.PMID 40774491 ↗Journal Int J Biol MacromolYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40774491/
-
Observational / other LOW evidence YELLOWSelf-Assembly of 2-Hydroxyethyl-1H-imidazolium-Based Surface Active Ionic Liquids and Utilization of Their Aqueous Solution in Superactivity of Cytochrome-c. ↗Singh M et al.. Self-Assembly of 2-Hydroxyethyl-1H-imidazolium-Based Surface Active Ionic Liquids and Utilization of Their Aqueous Solution in Superactivity of Cytochrome-c.. J Phys Chem B. 2025. PMID:40560061.PMID 40560061 ↗Journal J Phys Chem BYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40560061/
-
Observational / other LOW evidence YELLOWGroup 13 Lewis acid-mediated formation of 5-oxazolone derivatives from tert-butyl isocyanoacetate. ↗He Z et al.. Group 13 Lewis acid-mediated formation of 5-oxazolone derivatives from tert-butyl isocyanoacetate.. Chem Commun (Camb). 2025. PMID:40525467.PMID 40525467 ↗Journal Chem Commun (Camb)Year 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40525467/
-
Observational / other LOW evidence YELLOWAn approach to measure low LET radiation at high dose using CR-39 track detector. ↗Sahoo GS et al.. An approach to measure low LET radiation at high dose using CR-39 track detector.. Appl Radiat Isot. 2025. PMID:40179625.PMID 40179625 ↗Journal Appl Radiat IsotYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40179625/
-
Observational / other LOW evidence YELLOWAdvancing Propylene Epoxidation: the Role of Ethyl Acetate Autoxidation via Cobalt-Nickel Catalyzed C(acyl)u2500O Bond Scission. ↗He Y et al.. Advancing Propylene Epoxidation: the Role of Ethyl Acetate Autoxidation via Cobalt-Nickel Catalyzed C(acyl)u2500O Bond Scission.. Angew Chem Int Ed Engl. 2025. PMID:40034004.PMID 40034004 ↗Journal Angew Chem Int Ed EnglYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40034004/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Ester-C. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Ester-C
A score of 1.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.